<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128049</url>
  </required_header>
  <id_info>
    <org_study_id>B&amp;L 32280</org_study_id>
    <nct_id>NCT01128049</nct_id>
  </id_info>
  <brief_title>Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation</brief_title>
  <official_title>Non-invasive Tear Film Dynamic Measurements in Normal, MGD (Meibomium Gland Dysfunction) and Aqueous Deficient Dry Eye(ADDE) Subjects After Saline Instillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the objective tear film dynamic measurements in three different populations (MGD
      [Meibomium Gland Dysfunction], ADDE [Aqueous Deficient Dry Eye] and normal/control [non-dry
      eye]) and the subjective experience before and after instilling a single drop of saline in
      each eye.

      Currently available office-based tests for dry eye do not reliably correlate with patients'
      subjective symptoms. This study is interested in assessing how individuals with these two
      different ocular surface diseases compare with the normal population when measured
      objectively using two different instruments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be one study day with a single visit that will consist of taking two sets of
      measurements. Baseline measurements are taken in both eyes using a wavefront sensor to
      measure visual quality followed by saline instillation. Five minutes after drops, visual
      quality is again measured to evaluate changes in tear dynamics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Quality</measure>
    <time_frame>5 seconds</time_frame>
    <description>Average visual quality change over a 5 second blink cycle caused by movement of the tears over the surface of the eye by measuring optical irregularities.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Aqueous Deficient Dry Eye</condition>
  <condition>Meibomium Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Normal Patient Population</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-Dry Eye patient population (intervention remains the same across all arms)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MGD Patient Population</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meibomium Gland Dysfunction population(intervention remains the same across all arms)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADDE Population</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aqueous Deficient Dry Eye population(intervention remains the same across all arms)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Subjective Questionnaire</intervention_name>
    <description>The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.</description>
    <arm_group_label>Normal Patient Population</arm_group_label>
    <arm_group_label>MGD Patient Population</arm_group_label>
    <arm_group_label>ADDE Population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Measurement with wavefront sensor (right eye, then left eye)</intervention_name>
    <description>The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.</description>
    <arm_group_label>Normal Patient Population</arm_group_label>
    <arm_group_label>MGD Patient Population</arm_group_label>
    <arm_group_label>ADDE Population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Instill Saline Drop</intervention_name>
    <description>One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.</description>
    <arm_group_label>Normal Patient Population</arm_group_label>
    <arm_group_label>MGD Patient Population</arm_group_label>
    <arm_group_label>ADDE Population</arm_group_label>
    <other_name>Ocufresh eye wash</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Good general Health

          -  The subject must appear able and willing to adhere to the instructions set forth in
             this protocol (such as not use warm compresses or artificial tears/lubricant or
             excessive eye makeup before the visit on the study day).

        General Exclusion Criteria:

          -  Ocular disease, infection or inflammation (allergy, blepharitis) that is clinically
             significant (grade 3 or 4) that in the opinion of the PI would not be a good subject.

          -  Systemic disease or use of medication that in the opinion of the PI would not be a
             good subject.

          -  Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease
             (e.g. HIV).

          -  Contact lens wearer.

          -  Pregnancy or lactation.

          -  Diabetes.

          -  Inclusion or exclusion criteria of the other cohorts.

        Cohort Specific Inclusion Criteria:

          -  ADDE cohort: Schirmer I &lt; 10 mm, BUT ¬&lt; 5 seconds, Fluorescein 0 or 1, currently using
             an artificial tear for ocular comfort at least occasionally.

          -  MGD cohort: Diagnosis of moderate or severe MGD

          -  Normal/Control (Non Dry-Eye): meets general inclusion and exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James V Aquavella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Flaum Eye Institute-University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <results_first_submitted>May 25, 2015</results_first_submitted>
  <results_first_submitted_qc>May 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2015</results_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>James V. Aquavella, MD</investigator_full_name>
    <investigator_title>Medical Doctor and Department Faculty</investigator_title>
  </responsible_party>
  <keyword>Aqueous deficient dry eye (ADDE)</keyword>
  <keyword>Meibomium Gland Dysfunction (MGD)</keyword>
  <keyword>Normal/Control (Non Dry Eye)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Patient Population</title>
          <description>Subjects with no symptoms and no diagnosis of dry eye. Schirmer’s value ≥ 10mm/5 mins and a fluorescein tear break-up time &gt;5 secs with no surface staining.</description>
        </group>
        <group group_id="P2">
          <title>MGD Patient Population</title>
          <description>Subjects with a meibomian gland dysfunction on a slitlamp examination with a fluorescein tear break-up time &lt;5 secs.</description>
        </group>
        <group group_id="P3">
          <title>ADDE Population</title>
          <description>Subjects with schirmer’s value &lt; 10mm/5 mins and no meibomian gland dysfunction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Patient Population</title>
          <description>Subjects with no symptoms and no diagnosis of dry eye. Schirmer’s value ≥ 10mm/5 mins and a fluorescein tear break-up time &gt;5 secs with no surface staining.</description>
        </group>
        <group group_id="B2">
          <title>MGD Patient Population</title>
          <description>Subjects with a meibomian gland dysfunction on a slitlamp examination with a fluorescein tear break-up time &lt;5 secs.</description>
        </group>
        <group group_id="B3">
          <title>ADDE Population</title>
          <description>Subjects with schirmer’s value &lt; 10mm/5 mins and no meibomian gland dysfunction.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Quality</title>
        <description>Average visual quality change over a 5 second blink cycle caused by movement of the tears over the surface of the eye by measuring optical irregularities.</description>
        <time_frame>5 seconds</time_frame>
        <population>The comparison was between normal, non-dry eye participants and dry eye groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal</title>
            <description>Normal group included non-dry eye subjects.</description>
          </group>
          <group group_id="O2">
            <title>Meibomian Gland Dysfunction (MGD)</title>
            <description>Subjects with mild to moderate Meibomian Gland Dysfunction (MGD) on a slit lamp examination were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>Aqueous Deficiency Dry Eye (ADDE)</title>
            <description>Subjects with a low tear volume measured by Schimer's score of less than 10 mm were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Quality</title>
          <description>Average visual quality change over a 5 second blink cycle caused by movement of the tears over the surface of the eye by measuring optical irregularities.</description>
          <population>The comparison was between normal, non-dry eye participants and dry eye groups.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visual Quality at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.07"/>
                    <measurement group_id="O2" value="0.32" spread="0.08"/>
                    <measurement group_id="O3" value="0.19" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Quality at 5 minutes after Saline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.08"/>
                    <measurement group_id="O2" value="0.33" spread="0.08"/>
                    <measurement group_id="O3" value="0.23" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 1 year</time_frame>
      <desc>No Adverse Events were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Normal Patient Population</title>
          <description>Non-Dry Eye patient population (intervention remains the same across all arms)</description>
        </group>
        <group group_id="E2">
          <title>MGD Patient Population</title>
          <description>Meibomium Gland Dysfunction population(intervention remains the same across all arms)</description>
        </group>
        <group group_id="E3">
          <title>ADDE Population</title>
          <description>Aqueous Deficient Dry Eye population(intervention remains the same across all arms)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor review required before publishing results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Aquavella, MD</name_or_title>
      <organization>University of Rochester Medical Center, Flaum Eye Institute</organization>
      <phone>585-275-8944</phone>
      <email>James_Aquavella@URMC.Rochester.Edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

